Medincell S.A (MEDCL) | Stock Overview & Key Data
Medincell S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €39.68 on October 31, 2025
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Medincell S.A
MEDCL
|
831.60M Mid-cap | -0.86% | 1.61% | 25.88% | 25.88% | 25.88% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% | 23.51% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -4.54% | -14.08% | -20.62% | -18.33% | -26.00% | 1,368.91% | 434.91% | 184.92% | 1,317.50% | 310.87% | 310.87% |
|
Nanobiotix
NANO
|
1.39B Large-cap | 3.58% | -27.34% | 8.48% | 64.63% | 67.58% | 587.64% | 529.63% | 150.41% | 87.73% | 393.55% | 393.55% |
|
Inventiva S.A
IVA
|
980.10M Mid-cap | -4.11% | -32.02% | -36.99% | -12.10% | -19.26% | 17.12% | -17.79% | -71.83% | -58.75% | -58.75% | -58.75% |
|
BNP Paribas Easy
BLUE
|
527.29M Mid-cap | 0.44% | 3.07% | 3.19% | 10.56% | 8.57% | 13.90% | 27.99% | 35.25% | 7.35% | -14.94% | -14.94% |
|
Valneva SE
VLA
|
416.14M Mid-cap | -0.87% | -7.29% | -50.43% | -38.11% | -39.58% | -12.60% | -66.27% | -79.59% | 0.44% | -55.71% | -55.71% |
Ownership & Short Interest
Calculate Your Medincell S.A Investment Returns
Long-Term Investment Performance Analysis
Medincell S.A stock price in Mar 2026 was €22.20, A €1,000.00 lump sum investment in Medincell S.A made 0 years ago would be worth approximately €1,253.15 today, representing a positive return of 25.32%.
2 Months Investment Scenario (Mar 2026 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is MEDCL's 52-week high and low?
- In the last 52 weeks, Medincell S.A reached a high of €39.68 (on October 31, 2025) and a low of €15.00 (on N/A).
- What is the market cap and P/E ratio for MEDCL?
- Curious about Medincell S.A's size and valuation? Its market capitalization stands at 831.60M. When it comes to valuation, the P/E ratio (trailing twelve months) is -37.35, and the forward P/E (looking ahead) is 96.66.
- Does MEDCL pay dividends? If so, what's the yield?
- As for dividends, Medincell S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Medincell S.A's main competitors or similar companies to consider before investing?
When looking at Medincell S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 1,368.91% 434.91% Nanobiotix
NANO1.39B Healthcare Biotechnology 587.64% 529.63% Inventiva S.A
IVA980.10M Healthcare Biotechnology 17.12% -17.79% BNP Paribas Easy
BLUE527.29M Healthcare Biotechnology 13.90% 27.99% Valneva SE
VLA416.14M Healthcare Biotechnology -12.60% -66.27% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Medincell S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Medincell S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 112.65%, the Debt to Equity ratio from the most recent quarter is -2.40, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MEDCL?
- Looking at Medincell S.A's growth, its revenue over the trailing twelve months (TTM) was €32M. Compared to the same quarter last year (YoY), quarterly revenue grew by 49.90%, and quarterly earnings saw a YoY growth of N/A.
- How much of MEDCL stock is held by insiders and institutions?
- Wondering who owns Medincell S.A stock? Company insiders (like executives and directors) hold about 35.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.34%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.